Agency IQ

FEBRUARY 23, 2024

This workshop built on three prior workshops held by the FDA-AACR, which took place in 2015, 2016 and 2017. And I do think it’s really important to go as high up as we can safely, because there are issues that have already been mentioned – inter-tumor heterogeneity, issues of tumor penetration and [pharmacokinetics] PK.”

Science 40

Science FDA Trials Clinical Pharmacology 40

The Premier Consulting Blog

APRIL 25, 2023

In silico population pharmacokinetic (popPK) and physiologically-based pharmacokinetic (PBPK) modeling can reduce or eliminate certain clinical studies, as was done with the 505(b)(2) approval of the long-acting injectable Aristada® (aripiprazole lauroxil). [8] ICH Harmonised Guideline S10: Photosafety evaluation of pharmaceuticals.

FDA 52

FDA Animal Testing Pharmacokinetics Small Molecule 52

The Pharma Data

OCTOBER 14, 2020

AOP Orphan – AOP Orphan Pharmaceuticals took over the Viennese pharmaceutical company Amomed and the Luxembourgish health-tech company SciPharm. Lanifibranor is believed to be the first drug candidate to be granted this status for the treatment of NASH since January 2015. Growth Programme. Dolmatics – U.K.-based

Clinical Trials 52

Clinical Trials Trials Pharmaceuticals Therapies 52

Drug Target Review

OCTOBER 4, 2023

7 These inhibitors have faced challenges such as dose-limiting toxicity and poor pharmacokinetics, but geldanamycin ADCs have demonstrated increased survival in mice. HSP90 inhibitors HSP90, a major chaperone protein often overexpressed in tumours, has been targeted by inhibitors derived from the geldanamycin backbone.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

New Drug Approvals

APRIL 5, 2025

11] [12] [13] The US Food and Drug Administration granted orphan drug designation to treosulfan in 1994, for the treatment of ovarian cancer; [14] and in 2015, for conditioning treatment prior to hematopoietic stem cell transplantation in malignant and non-malignant diseases in adults and pediatric patients. [15] Medexus Pharmaceuticals.

FDA 62

FDA FDA Approval Production Treatment 62

Drug Target Review

JANUARY 20, 2025

These advances are reshaping how pharmaceutical and biotechnology companies approach clinical trial design, with a focus on patient-centric dosing strategies. How causal artificial intelligence is revolutionizing the pharmaceutical industry. References Redig, A. J., & Jnne, P. Journal of Clinical Oncology, 33 (9), 975977.

Clinical Trials 52

Clinical Trials Trials Drugs Drug Development 52

New Drug Approvals

APRIL 21, 2025

under reduced pressure to afford a solid residue of Formula IX.Example 7Preparation of a Pharmaceutically Acceptable Salt of Formula I The solid residue of Formula IX was dissolved in water (57 mL) and stirred for 10 min and cooled to 05 C. It is taken by mouth. [1] The aqueous solution was acidified with conc. 25 November 2024. PMC 7003869.

FDA Approval 62

FDA Approval FDA Production Treatment 62